AU2010250104B2 - Inhibition of prion protein propagation by receptor associated protein (RAP). its derivatives, mimetics and synthetic peptides - Google Patents
Inhibition of prion protein propagation by receptor associated protein (RAP). its derivatives, mimetics and synthetic peptides Download PDFInfo
- Publication number
- AU2010250104B2 AU2010250104B2 AU2010250104A AU2010250104A AU2010250104B2 AU 2010250104 B2 AU2010250104 B2 AU 2010250104B2 AU 2010250104 A AU2010250104 A AU 2010250104A AU 2010250104 A AU2010250104 A AU 2010250104A AU 2010250104 B2 AU2010250104 B2 AU 2010250104B2
- Authority
- AU
- Australia
- Prior art keywords
- rap
- seq
- polypeptide
- disease
- prion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 33
- 108091000054 Prion Proteins 0.000 title description 67
- 102000029797 Prion Human genes 0.000 title description 66
- 108090000623 proteins and genes Proteins 0.000 title description 35
- 102000004169 proteins and genes Human genes 0.000 title description 30
- 230000005764 inhibitory process Effects 0.000 title description 12
- 208000024777 Prion disease Diseases 0.000 claims abstract description 70
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 46
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 241000282414 Homo sapiens Species 0.000 claims description 23
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 208000017580 chronic wasting disease Diseases 0.000 claims description 16
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 14
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 14
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 241000282943 Odocoileus Species 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 208000002704 Sporadic Creutzfeldt-Jakob disease Diseases 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 9
- 208000027488 iatrogenic Creutzfeldt-Jakob disease Diseases 0.000 claims description 8
- 208000008864 scrapie Diseases 0.000 claims description 8
- 208000037956 transmissible mink encephalopathy Diseases 0.000 claims description 8
- 241000282994 Cervidae Species 0.000 claims description 7
- 241000282326 Felis catus Species 0.000 claims description 7
- 241000283868 Oryx Species 0.000 claims description 7
- 241000282979 Alces alces Species 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241000772415 Neovison vison Species 0.000 claims description 5
- 241000283870 Oryx gazella Species 0.000 claims description 5
- 241000933173 Tragelaphus angasii Species 0.000 claims description 5
- 241000283907 Tragelaphus oryx Species 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 208000032274 Encephalopathy Diseases 0.000 claims description 4
- 208000037957 feline spongiform encephalopathy Diseases 0.000 claims description 4
- 206010023497 kuru Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 239000008135 aqueous vehicle Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241000157302 Bison bison athabascae Species 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 208000015181 infectious disease Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 20
- 230000035772 mutation Effects 0.000 abstract description 6
- 239000003937 drug carrier Substances 0.000 abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 69
- 238000002474 experimental method Methods 0.000 description 44
- 238000004113 cell culture Methods 0.000 description 29
- 208000010544 human prion disease Diseases 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 24
- 102100025818 Major prion protein Human genes 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 16
- 230000001413 cellular effect Effects 0.000 description 13
- 229910002091 carbon monoxide Inorganic materials 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 9
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 108010003718 LDL-Receptor Related Protein-Associated Protein Proteins 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 201000006061 fatal familial insomnia Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 101000836956 Homo sapiens Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 241000283726 Bison Species 0.000 description 4
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000283725 Bos Species 0.000 description 3
- 241000282461 Canis lupus Species 0.000 description 3
- 241000283705 Capra hircus Species 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 3
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000282405 Pongo abelii Species 0.000 description 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000269368 Xenopus laevis Species 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- -1 cachets Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 101150084157 lrp-1 gene Proteins 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 2
- 108050007366 40S ribosomal protein SA Proteins 0.000 description 2
- 241001455214 Acinonyx jubatus Species 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 102100030009 Azurocidin Human genes 0.000 description 2
- 101710154607 Azurocidin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000006259 LDL-Receptor Related Proteins Human genes 0.000 description 2
- 108010058141 LDL-Receptor Related Proteins Proteins 0.000 description 2
- 241001455213 Leopardus pardalis Species 0.000 description 2
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 2
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001531354 Oryx leucoryx Species 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 241000282374 Puma concolor Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000283904 Tragelaphus strepsiceros Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000033885 plasminogen activation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000007153 proteostasis deficiencies Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 208000023697 ABri amyloidosis Diseases 0.000 description 1
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 description 1
- 208000023761 AL amyloidosis Diseases 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102100021321 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 102000004321 Atrophin-1 Human genes 0.000 description 1
- 108090000806 Atrophin-1 Proteins 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000867289 Glycine max Hsp70-Hsp90 organizing protein 1 Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 description 1
- 101000895100 Homo sapiens Ataxin-3 Proteins 0.000 description 1
- 101000963759 Homo sapiens Melanocortin-2 receptor accessory protein Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 description 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 208000031430 Inherited human prion disease Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 101150075405 LRPAP1 gene Proteins 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 102100040147 Melanocortin-2 receptor accessory protein Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000282569 Pongo Species 0.000 description 1
- 108010064571 PrPC Proteins Proteins 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 101100206942 Rattus norvegicus Tmprss11d gene Proteins 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229940127593 SEQ-9 Drugs 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000037198 Sporadic fatal insomnia Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- 102000006108 VHL Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000019143 inherited prion disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18040609P | 2009-05-21 | 2009-05-21 | |
| US61/180,406 | 2009-05-21 | ||
| US21875209P | 2009-06-19 | 2009-06-19 | |
| US61/218,752 | 2009-06-19 | ||
| PCT/US2010/001455 WO2010134970A1 (en) | 2009-05-21 | 2010-05-17 | Inhibition of prion protein propagation by receptor associated protein (rap). its derivatives, mimetics and syntentic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010250104A1 AU2010250104A1 (en) | 2011-10-27 |
| AU2010250104A8 AU2010250104A8 (en) | 2012-06-07 |
| AU2010250104B2 true AU2010250104B2 (en) | 2014-04-24 |
Family
ID=43126428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010250104A Ceased AU2010250104B2 (en) | 2009-05-21 | 2010-05-17 | Inhibition of prion protein propagation by receptor associated protein (RAP). its derivatives, mimetics and synthetic peptides |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9051390B2 (enExample) |
| EP (1) | EP2432487B1 (enExample) |
| JP (1) | JP5862560B2 (enExample) |
| AU (1) | AU2010250104B2 (enExample) |
| CA (1) | CA2755948A1 (enExample) |
| WO (1) | WO2010134970A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017218897A1 (en) * | 2016-06-17 | 2017-12-21 | The Trustees Of The University Of Pennsylvania | Novel 1gg binding peptides and multifunctional antigen-binding proteins comprising the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042227A1 (en) * | 2003-06-20 | 2005-02-24 | Todd Zankel | Megalin-based delivery of therapeutic compounds to the brain and other tissues |
| US20080268474A1 (en) * | 2002-12-03 | 2008-10-30 | Hammond David J | Prion protein ligands and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
-
2010
- 2010-05-17 WO PCT/US2010/001455 patent/WO2010134970A1/en not_active Ceased
- 2010-05-17 JP JP2012511816A patent/JP5862560B2/ja not_active Expired - Fee Related
- 2010-05-17 US US13/265,242 patent/US9051390B2/en not_active Expired - Fee Related
- 2010-05-17 CA CA2755948A patent/CA2755948A1/en not_active Abandoned
- 2010-05-17 AU AU2010250104A patent/AU2010250104B2/en not_active Ceased
- 2010-05-17 EP EP10778035.5A patent/EP2432487B1/en not_active Not-in-force
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080268474A1 (en) * | 2002-12-03 | 2008-10-30 | Hammond David J | Prion protein ligands and methods of use |
| US20050042227A1 (en) * | 2003-06-20 | 2005-02-24 | Todd Zankel | Megalin-based delivery of therapeutic compounds to the brain and other tissues |
Non-Patent Citations (6)
| Title |
|---|
| : DATABASE UniProt [Online] 21 December 2004 (2004-12-21 ), "SubName: Full=Putative uncharacterized protein DKFZp45912430;", retrieved from EBI accession no. UNIPROT:Q5RD62 Database accession no. Q5RD62 * |
| DATABASE Geneseq [Online] 29 January 2004 (2004-01-29), "Rat Protein 099068, SEQ ID NO 10388.", retrieved from EBI accession no. GSP:ADD44957 Database accession no. ADD44957 * |
| DATABASE UniProt [Online] 1 June 1998 (1998-06-01 ), "SubName: Full=Receptor-associated protein; Flags: Precursor;", retrieved from EBI accession no. UNIPROT:O57378 Database accession no. O57378 * |
| DATABASE UniProt [Online] 1 June 2003 (2003-06-01 ), "SubName: Full=Low density lipoprotein receptor-related protein associated protein 1; LQWKKLKAEG MDEDGEREAK LRRNFNllLA KYGMDGKKDT RTLDSNRLKD HEVKIGDTFD", EBI Acc. No. Q7ZW96 * |
| DATABASE UniProt [Online] 1 October 2003 (2003-10-01 ), "SubName: Full=LOC398643 protein; Flags: Fragment;", retrieved from EBI accession no. UNIPROT:Q7SYR7 Database accession no. Q7SYR7 * |
| DATABASE UniProt [Online] 5 July 2004 (2004-07-05), "SubName: Full=Lrpap1 protein; Flags: Fragment;", XP002687 468, EPO Form 1703 01.91TRI retrieved from EBI accession no. UNIPROT:Q6PEM5 Database accession no. Q6PEM5 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120135936A1 (en) | 2012-05-31 |
| AU2010250104A1 (en) | 2011-10-27 |
| JP2012527459A (ja) | 2012-11-08 |
| US9051390B2 (en) | 2015-06-09 |
| EP2432487A4 (en) | 2013-01-02 |
| EP2432487B1 (en) | 2016-03-02 |
| EP2432487A1 (en) | 2012-03-28 |
| WO2010134970A8 (en) | 2011-11-10 |
| WO2010134970A1 (en) | 2010-11-25 |
| JP5862560B2 (ja) | 2016-02-16 |
| CA2755948A1 (en) | 2010-11-25 |
| AU2010250104A8 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chaplot et al. | Secreted chaperones in neurodegeneration | |
| Leitner et al. | Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders | |
| Heiseke et al. | Autophagy, prion infection and their mutual interactions | |
| Funderburk et al. | Cell “self‐eating”(autophagy) mechanism in Alzheimer's disease | |
| CN108431021B (zh) | 具有神经元损失预防和再生效果的肽以及包含该肽的组合物 | |
| Yong et al. | Neuroprotective effects of lactoferrin in Alzheimer’s and Parkinson’s diseases: A narrative review | |
| Ayyubova | APOE4 is a risk factor and potential therapeutic target for Alzheimer's disease | |
| へ下へ et al. | An overview of Alzheimer's disease | |
| Junde et al. | Lithium chloride promotes neural functional recovery after local cerebral ischaemia injury in rats through Wnt signalling pathway activation | |
| US11390656B2 (en) | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases | |
| Granic et al. | LPYFDa neutralizes amyloid-β-induced memory impairment and toxicity | |
| Olrichs et al. | Novel insights into the function of the conserved domain of the CAP superfamily of proteins | |
| AU2010250104B2 (en) | Inhibition of prion protein propagation by receptor associated protein (RAP). its derivatives, mimetics and synthetic peptides | |
| WO2006036410A2 (en) | Protection from and treatment of prion protein infection | |
| Su et al. | Antimicrobial peptides in the brain | |
| Hasebe et al. | Reaction of complement factors varies with prion strains in vitro and in vivo | |
| US9522170B2 (en) | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein | |
| Misasi et al. | Biochemistry and neurobiology of prosaposin: a potential therapeutic neuro-effector | |
| Sundaram | Sialic acid and its analogues as potential neuro anti-inflammatory therapeutic candidates for Alzheimer’s | |
| Ragagnin et al. | Neuronal autophagy and prion proteins | |
| Morozova | Mechanism of Tau Propagation: Putative Therapeutic Approaches | |
| US20150147346A1 (en) | Replikin sequences and their antibodies for diagnostics, therapeutics, and vaccines against prion and neurodegenerative disorders including alzheimer's disease | |
| da Silva Moreira | Dysregulated inflammation in the pathogenesis of Familial Amyloid Polyneuropathy | |
| Borbély | Development of Non-Transgenic Animal Models of Alzheimer’s Disease and Investigation of Drug Candidates for its Treatment | |
| Soto et al. | Peptides Inhibitor of Amyloidogenesis in Alzheimer’s Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 25, NO 42, PAGE(S) 5267 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME AMERICAN NATIONAL RED CROSS, APPLICATION NO. 2010250104, UNDER INID (54) CORRECT THE TITLE TO READ INHIBITION OF PRION PROTEIN PROPAGATION BY RECEPTOR ASSOCIATED PROTEIN (RAP). ITS DERIVATIVES, MIMETICS AND SYNTHETIC PEPTIDES |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |